News & Updates
Filter by Specialty:
Which factors raise HCC risk in patients with cured HCV?
Predictors of hepatocellular carcinoma (HCC) differ in patients with virologically cured hepatitis C virus (HCV) infection with and without cirrhosis, according to a study. However, changes in fibrosis-4 (FIB-4) scores over time are associated with HCC risk in both cohorts.
Which factors raise HCC risk in patients with cured HCV?
24 Nov 2022
Entecavir plus traditional Chinese medicine cuts HCC risk in CHB
Among patients with chronic hepatitis B (CHB), treatment with entecavir (ETV) and Biejia-Ruangan compound (BRC), an antifibrotic traditional Chinese medicine, helps reduce the risk of hepatocellular carcinoma (HCC), a recent study reports.
Entecavir plus traditional Chinese medicine cuts HCC risk in CHB
22 Nov 2022
H. pylori eradication eases metabolic dysfunction, steatosis in NAFLD
Among patients with nonalcoholic fatty liver disease (NAFLD), eradication treatment against Helicobacter pylori may help improve liver steatosis and metabolic parameters, a recent study has found.
H. pylori eradication eases metabolic dysfunction, steatosis in NAFLD
20 Nov 2022
Noninvasive scores use LSM to detect cirrhosis, advance fibrosis in NAFLD
Using liver stiffness measurements (LSM) combined with routine clinical parameters, Agile 3+, and Agile 4, both noninvasive scoring methods, can accurately identify advanced fibrosis (AF) and cirrhosis, respectively, in patients with nonalcoholic fatty liver disease (NAFLD), reports a new study.
Noninvasive scores use LSM to detect cirrhosis, advance fibrosis in NAFLD
16 Nov 2022
Bariatric surgery provides cardioprotection in patients with severe obesity, NAFLD
Patients with severe obesity and nonalcoholic fatty liver disease (NAFLD) appear to benefit from bariatric surgery, which significantly reduces the risk of cardiovascular disease (CVD), a study has found.
Bariatric surgery provides cardioprotection in patients with severe obesity, NAFLD
09 Nov 2022
High glycaemic burden associated with HCC development and fibrosis progression in patients with CHB + T2D
High glycaemic burden is associated with hepatocellular carcinoma (HCC) development and fibrosis progression in patients with chronic hepatitis B (CHB) and type 2 diabetes (T2D) (CHB + T2D), researchers from the University of Hong Kong (HKU) have reported.